Grand Rounds

A Focus on Relapsed Multiple Myeloma

Kimberly Noonan,(1) DNP, ANP-BC, AOCN®, Sandra Rome,(2) RN, MN, AOCN®, CNS, and Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN

From (1)Dana-Farber Cancer Institute, Boston, Massachusetts; (2)Cedars-Sinai Medical Center, Los Angeles, California; (3)Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

Authors’ disclosures of conflicts of interest are found at the end of this article.

Correspondence to: Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195. E-mail: faimanb@ccf.org


J Adv Pract Oncol 2022;13(Suppl 4):15–21 | https://doi.org/10.6004/jadpro.2022.13.5.11 | © 2022 Harborside™


  

ABSTRACT

Multiple myeloma (MM) is a relapsing disease for many patients with multiple myeloma. At relapse, patients have many options for treatment once disease has progressed. Advanced practitioners are well suited to set expectations for ongoing therapy and underscore the importance of continued disease monitoring. Criteria for relapsed myeloma rely on biomarker and radiologic imaging, as well as physical exam and awareness of new bone pain or changes in physiologic function. The treatment of patients with relapsed MM requires a personalized approach and considers patient desires in regard to aggressiveness of therapy and willingness to participate in a clinical trial. The prognosis of patients with relapsed MM depends upon disease characteristics at baseline or throughout, as patients may acquire adverse cytogenetic abnormalities through various lines of treatment. Empowering patients to understand their diagnosis, interpret labs, and take an active role in treatment selection through shared decision-making can improve patients’ quality of life and enhance adherence.

Multiple Myeloma and Plasma Cell Disorders: Update on Diagnosis, Prognosis, Treatment, and Supportive Care
Introduction
A Focus on Newly Diagnosed Multiple Myeloma
A Focus on Relapsed Multiple Myeloma
A Focus on Special Populations in Relapsed Multiple Myeloma
A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
A Focus on Waldenström Macroglobulinemia and AL Amyloidosis




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.